Prognostic significance of three tumor markers (CA125, CEA, and TPA) in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Neuron-specific enolase (NSE) serum level as a prognostic factor for tumor regression and survival in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
Prognostic significance of S-100 immmunostaining in non-small cell lung cancer (NSCLC) Source: Annual Congress 2004 - Prognostic factors Year: 2004
Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Clinical correlates and prognostic significance of neuron specific enolase (NSE) in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Carcinoembryonic antigen mRNA analysis detects micrometastatic cells in blood from lung cancer patients Source: Eur Respir J 2003; 22: 418-421 Year: 2003
The correlation of serum tumor markers and distant metastasis in lung adenocarcinoma Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Therapeutic pulmonary metastasectomy for colorectal cancer should be chosen in any disease-free interval, size of tumor, and carcinoembryonic antigen level Source: Annual Congress 2011 - General thoracic surgery I Year: 2011
Expression of βig-h3 as a marker of local tumor invasion in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006
The correlation between mediastinal lymphadenopathy positivity proved by mediastinoscopy and serum levels of vascular endothelial growth factor (VEGF) and carcinoembryonic antigen (CEA) in NSCLC cases Source: Annual Congress 2007 - Diagnosis of thoracic malignancies Year: 2007
Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 82s Year: 2004
The prognostic significance of sVEGF levels in patients(pts) with Non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
Prognostic significance of Nestin in resected non-small cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
MonoTotal vs. other cytokeratin markers in NSCLC Source: Annual Congress 2008 - Various aspects of thoracic oncology Year: 2008